FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2488116285> ?p ?o ?g. }

• W2488116285 abstract "Glioblastoma (GBM) is the most common brain cancer. Front-line systemic therapy with temozolomide (TMZ) is often ineffective due to O6-methylguanine-DNA-methyltransferase (MGMT)-mediated resistance and patients with recurrent glioma have limited treatment options and very poor prognosis. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating agent that readily crosses the blood-brain barrier and has demonstrated activity against GBM in prior NCI-sponsored clinical trials. VAL-083 induces cross-links at N7 of guanine causing double-strand DNA breaks and apoptosis independent of MGMT expression against multiple GBM cell lines and cancer stem cells in vitro. VAL-083 cytotoxic activity also appears to be less dependent on wild type p53 compared to other alkylating agents. The main goal of this clinical trial was to determine an appropriate dose for VAL-083 for advancement to Phase II/III trials as a potential new treatment for refractory GBM. METHOD: Open-label, single-arm Phase I dose-escalation study (3+3 design) of IV treatment with VAL-083 on days 1, 2, 3 of a 21-day cycle, until MTD was reached. In Phase II, additional patients with GBM are treated at the MTD to gather further safety and outcomes data. Patients must have histologically confirmed GBM, previously treated with surgery and radiation and must have failed both TMZ and bevacizumab, unless contraindicated. RESULTS: Phase I has been completed and 40 mg/m2/d confirmed as the MTD. 29 GBM patients were enrolled in Phase I across 9 dose cohorts (1.5 - 50 mg/m2/d). Myelosuppression was mild; no drug-related serious adverse events were reported at doses ?40 mg/m2/d. Dose limiting toxicities (DLT), consisting of thrombocytopenia, were observed at 50 mg/m2/d and at an interim 45 mg/m2/d cohort. Platelet nadir occurred around day 20 and resolved rapidly and spontaneously. Pharmacokinetic analyses show dose-dependent linear systemic exposure with a short 1-2h plasma terminal half-life; average Cmax 781 ng/mL (5.3μM) at 40 mg/m2/d resulting in estimated CNS concentrations within the IC50 range observed for GBM cell-lines in vitro. A 14 patient Phase II expansion cohort was enrolled at 40 mg/m2/d. Safety observations in the Phase II expansion cohort to date are consistent with Phase I: Observed myelosuppression is mild, with the exception of 1 patient previously treated with CCNU who developed grade 4 thrombocytopenia. To date, 20 GBM patients (6 patients in Phase I and 14 patients in Phase II) have been treated with VAL-083 at therapeutic doses of 30 or 40 mg/m2/d. CONCLUSIONS: VAL-083 at 40 mg/m2/d on days 1, 2, 3 of a 21-day cycle exhibits a favorable safety profile and the Phase I part of the study showed a trend toward clinically meaningful improved survival in refractory GBM patients. Updated safety and outcomes data from the Phase II expansion cohort will be presented. ClinicalTrials.gov Identifier NCT01478178. Citation Format: Kent C. Shih, Manish R. Patel, Nicholas Butowski, Gerald S. Falchook, Sani H. Kizilbash, Jeffrey A. Bacha, Dennis M. Brown, Anne Steino, Richard Schwartz, Sarath Kanekal, Lorena M. Lopez, Howard A. Burris. Phase I/II study of VAL-083 in patients with recurrent glioblastoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT074." @default.
• W2488116285 created "2016-08-23" @default.
• W2488116285 creator A5005718112 @default.
• W2488116285 creator A5009807263 @default.
• W2488116285 creator A5014794937 @default.
• W2488116285 creator A5027623369 @default.
• W2488116285 creator A5031473630 @default.
• W2488116285 creator A5064134740 @default.
• W2488116285 creator A5069777765 @default.
• W2488116285 creator A5072308451 @default.
• W2488116285 creator A5076017612 @default.
• W2488116285 creator A5089653752 @default.
• W2488116285 creator A5090305344 @default.
• W2488116285 creator A5091035596 @default.
• W2488116285 date "2016-07-15" @default.
• W2488116285 modified "2023-09-27" @default.
• W2488116285 title "Abstract CT074: Phase I/II study of VAL-083 in patients with recurrent glioblastoma" @default.
• W2488116285 doi "https://doi.org/10.1158/1538-7445.am2016-ct074" @default.
• W2488116285 hasPublicationYear "2016" @default.
• W2488116285 type Work @default.
• W2488116285 sameAs 2488116285 @default.
• W2488116285 citedByCount "0" @default.
• W2488116285 crossrefType "proceedings-article" @default.
• W2488116285 hasAuthorship W2488116285A5005718112 @default.
• W2488116285 hasAuthorship W2488116285A5009807263 @default.
• W2488116285 hasAuthorship W2488116285A5014794937 @default.
• W2488116285 hasAuthorship W2488116285A5027623369 @default.
• W2488116285 hasAuthorship W2488116285A5031473630 @default.
• W2488116285 hasAuthorship W2488116285A5064134740 @default.
• W2488116285 hasAuthorship W2488116285A5069777765 @default.
• W2488116285 hasAuthorship W2488116285A5072308451 @default.
• W2488116285 hasAuthorship W2488116285A5076017612 @default.
• W2488116285 hasAuthorship W2488116285A5089653752 @default.
• W2488116285 hasAuthorship W2488116285A5090305344 @default.
• W2488116285 hasAuthorship W2488116285A5091035596 @default.
• W2488116285 hasConcept C121608353 @default.
• W2488116285 hasConcept C126322002 @default.
• W2488116285 hasConcept C143998085 @default.
• W2488116285 hasConcept C2776194525 @default.
• W2488116285 hasConcept C2776694085 @default.
• W2488116285 hasConcept C2777389519 @default.
• W2488116285 hasConcept C2777802072 @default.
• W2488116285 hasConcept C2778227246 @default.
• W2488116285 hasConcept C31760486 @default.
• W2488116285 hasConcept C502942594 @default.
• W2488116285 hasConcept C509974204 @default.
• W2488116285 hasConcept C535046627 @default.
• W2488116285 hasConcept C71924100 @default.
• W2488116285 hasConceptScore W2488116285C121608353 @default.
• W2488116285 hasConceptScore W2488116285C126322002 @default.
• W2488116285 hasConceptScore W2488116285C143998085 @default.
• W2488116285 hasConceptScore W2488116285C2776194525 @default.
• W2488116285 hasConceptScore W2488116285C2776694085 @default.
• W2488116285 hasConceptScore W2488116285C2777389519 @default.
• W2488116285 hasConceptScore W2488116285C2777802072 @default.
• W2488116285 hasConceptScore W2488116285C2778227246 @default.
• W2488116285 hasConceptScore W2488116285C31760486 @default.
• W2488116285 hasConceptScore W2488116285C502942594 @default.
• W2488116285 hasConceptScore W2488116285C509974204 @default.
• W2488116285 hasConceptScore W2488116285C535046627 @default.
• W2488116285 hasConceptScore W2488116285C71924100 @default.
• W2488116285 hasLocation W24881162851 @default.
• W2488116285 hasOpenAccess W2488116285 @default.
• W2488116285 hasPrimaryLocation W24881162851 @default.
• W2488116285 hasRelatedWork W1975041356 @default.
• W2488116285 hasRelatedWork W1982904297 @default.
• W2488116285 hasRelatedWork W1986034588 @default.
• W2488116285 hasRelatedWork W2049880080 @default.
• W2488116285 hasRelatedWork W2061271414 @default.
• W2488116285 hasRelatedWork W2094066552 @default.
• W2488116285 hasRelatedWork W2241766570 @default.
• W2488116285 hasRelatedWork W2339942369 @default.
• W2488116285 hasRelatedWork W2340153564 @default.
• W2488116285 hasRelatedWork W2404021175 @default.
• W2488116285 hasRelatedWork W2406182066 @default.
• W2488116285 hasRelatedWork W2501643430 @default.
• W2488116285 hasRelatedWork W2536315798 @default.
• W2488116285 hasRelatedWork W2565213538 @default.
• W2488116285 hasRelatedWork W2886124586 @default.
• W2488116285 hasRelatedWork W2886327945 @default.
• W2488116285 hasRelatedWork W2983160271 @default.
• W2488116285 hasRelatedWork W3082936327 @default.
• W2488116285 hasRelatedWork W3174258863 @default.
• W2488116285 hasRelatedWork W2186083368 @default.
• W2488116285 isParatext "false" @default.
• W2488116285 isRetracted "false" @default.
• W2488116285 magId "2488116285" @default.
• W2488116285 workType "article" @default.